Texas Center for Drug Development, Inc.
Welcome,         Profile    Billing    Logout  
 3 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Miller, Vicki S
NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Recruiting
3
125
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
ADVANCE, NCT06672549: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Not yet recruiting
3
125
Europe, Japan, US, RoW
Orforglipron, LY3502970, Placebo
Eli Lilly and Company
Obesity, Overweight
02/27
03/27
NCT06007183: Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination

Recruiting
3
800
US
CHIKV VLP vaccine booster, PXVX0317, Placebo booster
Bavarian Nordic
Chikungunya Virus Infection
04/28
08/28
NCT06431607: A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

Active, not recruiting
2
838
US
Flu Seasonal mRNA Formulation 1, GSK4382276A, Flu Seasonal mRNA Formulation 2, Flu Seasonal mRNA Formulation 3, Flu Seasonal mRNA Formulation 4, Flu Seasonal mRNA Formulation 5, Flu Seasonal mRNA Formulation 6, Flu Seasonal mRNA Formulation 7, Flu Seasonal mRNA Formulation 8, Active Comparator 1, Active Comparator 2, Flu Seasonal mRNA Formulation 9, Flu Seasonal mRNA Formulation 10, Active Comparator 3, Active Comparator 4
GlaxoSmithKline
Influenza, Human
11/24
06/25
NCT06680375: A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults

Active, not recruiting
1/2
780
US
Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo, Phase 2 selected Investigational Flu Seasonal/SARS-CoV-2 mRNA, Phase 2 selected SARS-CoV-2 mRNA
GlaxoSmithKline
COVID-19
05/25
11/25
Harianawala, Zohair
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Terminated
2/3
538
US
BHV-3500 (zavegepant), Placebo
Pfizer
Migraine
03/24
03/24
Seminario, Teodoro
NCT06742281: A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

Recruiting
2
10016
US
CVXGA (CVXGA50), COMIRNATY®
CyanVac LLC, Biomedical Advanced Research and Development Authority
COVID-19
06/26
06/27
Eckert, Stacey
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder

Recruiting
3
700
US
Troriluzole, Placebo
Biohaven Pharmaceuticals, Inc.
Obsessive-Compulsive Disorder
06/25
06/25
Saubon, Frances
NCT04804033: A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

Terminated
2/3
538
US
BHV-3500 (zavegepant), Placebo
Pfizer
Migraine
03/24
03/24
Hurtado, Kathia
NCT05979779: Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Active, not recruiting
2
219
US
HU6, Placebo
Rivus Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
02/25
04/25

Download Options